Company intelligence / Profile preview

PharmaLundensis AB

Ownership: Private
Development stage: Preclinical

Overview

PharmaLundensis AB develops novel therapies targeting heavy metal detoxification and respiratory diseases such as COPD, chronic bronchitis, depression, and chronic fatigue syndrome. Its lead drug candidate PHAL‑501 aims to bind/excrete heavy metals. The company also develops Iodocarb for COPD/chronic bronchitis/influenza-induced lung failure and the EcoFilter system to reduce pharmaceutical/multi-resistant bacterial contamination from hospitals. Clinical results are not detailed in public sources but the company appears focused on early-stage development with some programs possibly advancing into clinical trials.[1][2][3]

Therapeutic areas: PulmonologyPsychiatryImmunologyOtherInfectious Diseases
Modalities: Small molecules (e.g., Iodocarb)medical devices (EcoFilter system)
Industry: Biotech

Drug pipeline

1 asset

Phal-501

Preclinical

Beyond the preview

Go deeper on PharmaLundensis AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaLundensis AB.

Explore the full profile